Novavax
Novavax Inc is an American biotechnology company specializing in recombinant protein nanoparticle vaccines and adjuvants for infectious diseases. The company develops, manufactures, and markets protein-based vaccines, including its Matrix-M-adjuvanted COVID-19 vaccine and combination respiratory vaccine candidates. Main revenue drivers include commercial vaccine product sales, licensing agreements, and government vaccine development grants. Novavax serves public health agencies, healthcare providers, pharmacy networks, and international procurement organizations across North America, Europe, and Asia. The company holds a prominent market position as a developer of protein-based vaccine technology and adjuvant systems. Headquartered in Gaithersburg, Maryland, Novavax Inc is listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Novavax.
- Legal name
- NOVAVAX
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Novavax
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.17 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)